No Data
Outperform Rating With Raised Price Target for Revolution Medicines Amid Promising Oncology Trials
Express News | Revolution Medicines Inc : Leerink Partners Raises Target Price to $55 From $53
Revolution Medicines Is Maintained at Overweight by Barclays
Express News | Revolution Medicines Inc. : Barclays Raises Target Price to $54 From $52
Barclays Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $54
Barclays analyst Peter Lawson maintains $Revolution Medicines(RVMD.US)$ with a buy rating, and adjusts the target price from $52 to $54.According to TipRanks data, the analyst has a success rate of 44
Barclays Remains a Buy on Revolution Medicines (RVMD)
No Data